← board
BLRX
distress 3/10 · well-funded / low risk$3.04+7%today-35% from 52w high
Revenue
pre-revenue
Liquidity
$17M
Runway
2.1 yrs
Shares 1y
0%
Price & events
+2.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
+6.6%
1D
+2.0%
1W
-6.8%
1M
+32.1%
3M
-2.0%
6M
-33.4%
1Y
-90.6%
2Y
-97.7%
5Y
-96.9%
All
Overview
- Market Cap
- $7.93B
- Enterprise Value
- $7.94B
- Volume
- 2.69K
- 52 Week Range
- $2.18 – $4.70
- Total Shares
- 2.61B
- Float Shares
- 4.16M
- Short %
- 3.14%
- % Held by Insiders
- 3.91%
- % Held by Institutions
- 0.45%
- RVOL
- 0.12x
- Beta
- 0.62
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-06-17HC Wainwright & Co.Buy
- 2025-05-30Jones TradingHold → Buy
- 2025-05-28HC Wainwright & Co.Buy
- 2025-04-02Jones TradingBuy → Hold
- 2025-03-31HC Wainwright & Co.Buy
- 2024-11-25HC Wainwright & Co.Buy
Competitors
- none identified
Recent news
- 2026-07-22Price to earnings forward of BioLineRX Ltd. Sponsored ADR – SWB:YP2 - TradingView
- 2026-07-21BioLineRx to Present GLIX1 Ovarian Cancer Data at ESMO 2026 - t.co
- 2026-07-20BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026 - Investing.com
- 2026-07-20BioLineRx, Hemispherian to present GLIX1 data at ESMO 2026 By Investing.com - Investing.com Canada
- 2026-07-20BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 - Nasdaq
- 2026-07-20BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 - PR Newswire
- 2026-07-17BioLineRx (BLRX) Q4 2024 earnings summary - Quartr
- 2026-07-16BioLineRx (BLRX) Q4 2025 earnings summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.